Bayer wants to strengthen his young genetic and cell therapy business with an American expert in genetic modification. The Pharmaceutical and Agrochemical Institute in Berlin announced on Monday that treatments for liver diseases would initially be developed with the help of Mammoth Biosciences’ genetic scissor technology. Overall, Bayer hopes to use technology to quickly develop treatment options.
As part of the collaboration, Mammootty will receive $ 40 million (35 35 million) in the first phase, which could add up to more than $ 1 billion in the future, depending on the achievement of the goals. Related milestones were agreed, it said. In addition, there will be a share of research payments and revenue.
One of Mammootty’s co-founders was Jennifer Dowdna, who, along with Frenchman Emmanuel Sarpentier, won the 2020 Nobel Prize in Chemistry for developing genetic scissors for targeted genetic modification. The so-called Crispr / Cas technology, also known as genetic modification, involves the removal, insertion, and modification of DNA.
Considering the possibilities, Bayer – like other pharmaceutical companies – has been focusing more on gene and cell therapies for some time, with the aim of tackling previously incurable diseases. Acquisitions of US biotech companies Bluerock Therapeutics 2019 and Asklepios BioPharmaceutical (AskBio) 2020 stand out.
“Amateur coffee fan. Travel guru. Subtly charming zombie maven. Incurable reader. Web fanatic.”